menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Siegfried Confirmed in Dow Jones Sustainability Index Europe

    PHARMAWEB

    Siegfried opens global R&D Center for Drug Substance in Switzerland

    INDPHARMAPOST

    Dinamiqs opens new lab in Zurich

    PRESS RELEASE

    Strategy EVOLVE+ paves the way for continued profitable growth

    PRESS RELEASE

    EGS Beteiligungen Ups Stake In Siegfried To 7.2% Registered Shares

    PRESS RELEASE

    Siegfried opens new quality control lab in Minden

    PRESS RELEASE

    Marcel Imwinkelried appointed as new CEO

    PRESS RELEASE

    Siegfried successfully completes acquisition of an early-phase CDMO in Wisconsin (US)

    PRESS RELEASE

    EGS`s sexercises right to convert bond & increases its shareholding Siegfried

    PRESS RELEASE

    Siegfried expands US reach with deal for Wisconsin facility

    FIERCE PHARMA

    Siegfried to acquire an early-phase CDMO in (US) for its Drug Sub services

    PRESS RELEASE

    Siegfried increases distribution to the shareholders & all proposals of the BOD

    PRESS RELEASE

    Changes in Siegfried’s Management Team

    PRESS RELEASE

    Lonza names Siegfried Holding boss as new CEO

    REUTERS

    Enforcement Report - Week of December 20, 2023

    FDA

    Changes in Siegfried’s Executive Committee

    PRESS RELEASE

    Siegfried acquires stake in DiNAMIQS to establish organization for gene therapies

    PRESS RELEASE

    Siegfried begins construction of a R&D Center for Drug Substances in Evionnaz

    PRESS RELEASE

    Siegfried increases distribution and ap­points new board member

    PRESS RELEASE

    Siegfried opens global Development Center for Drug Products in Barcelona

    PRESS RELEASE

    Siegfried significantly increases sales and profits in 2022

    PRESS RELEASE

    Siegfried appoints Christian Dowdeswell as CBO Drug Substances

    PRESS RELEASE

    Siegfried Announces Change in its Board of Directors

    PRESS RELEASE

    Siegfried and Novavax extend their collaboration

    PRESS RELEASE

    Siegfried begins construction of new large-scale production plant in Minden (DE)

    PRESS RELEASE

    Siegfried increases sales and profits in the first half of 2022

    PRESS RELEASE

    Siegfried Increases Distribution and Appoints Two New Board Members

    PRESS RELEASE

    For the first time, Siegfried reports sales of more one billion Swiss francs

    PRESS RELEASE

    Siegfried Announces Changes in its Board of Directors

    PRESS RELEASE

    Siegfried is included in the Dow Jones Sustainability Index Europe

    PRESS RELEASE

    Siegfried supports Novavax with commercial aseptic fill & finish NVX-CoV2373

    PRESS RELEASE

    Siegfried Successfully Completes Acquisition of Novartis MFG Sites in Spain

    PRESS RELEASE

    CStone, Pfizer Enter Antibody Alliance

    CONTRACT PHARMA

    Keryx hires Siegfried to make Auryxia API

    IN PHARMATECHNOLOGIST

    Siegfried saw API revs slide in 1H, but earnings up on synergies

    IN PHARMATECHNOLOGIST

    Swiss Generic Manufacturer Siegfried Increased Sales And EBITDA

    SEEKINGALPHA

    Siegfried’s revenues up on APIs and new plants, earnings down on costs

    IN PHARMATECHNOLOGIST

    Swiss firm sees revs soar and says new API biz will drive growth

    IN PHARMATECHNOLOGIST

    Siegfried and BASF reflect on recent API deal

    IN PHARMATECHNOLOGIST

    BASF completes sale of custom synthesis business and parts of its API business to Siegfried Holding AG

    BASF

    Siegfried buys BASF drug ingredient businesses for $306 million

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.